Pluribus Labs’s CME Group CME Stock Holding History

Pluribus Labs’s Portfolio CME Stock Details CME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$244K	Buy	1,192 +328	+38%	+$69.5K	0.45%	78
2022 Q1	$206K	Buy	+864	New	+$203K	0.82%	42

Other funds holding CME

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Edgewood Management Greenwich, Connecticut $15.5B AUM 9.67% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Pluribus Labs's CME Position: Q2 2022 in Review

Pluribus Labs increased its CME Group (CME) stake by 38% in Q2 2022, buying an estimated $69.5K and bringing the position to 1,192 shares worth $244K. The position accounts for 0.45% of the portfolio, ranked #78.

Pluribus Labs first reported a position in CME in Q1 2022 and has held it in 2 quarters since. 1,158 funds tracked by Wall St. Rank hold CME as of Q2 2022.

Pluribus Labs held 1,192 shares of CME Group worth $244K as of Q2 2022.
Pluribus Labs bought 328 CME Group shares in Q2 2022, an estimated $69.5K.
CME Group made up 0.45% of Pluribus Labs's portfolio in Q2 2022, its #78 holding.
Pluribus Labs first reported a position in CME Group in Q1 2022 and has held it in 2 quarters since.
1,158 funds tracked by Wall St. Rank held CME Group as of Q2 2022.

Based on Pluribus Labs's 13F filing for Q2 2022, filed 12 Aug 2022.